Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their inpatient detox protocol.
The primary objective of this study is to evaluate the feasibility and preliminary effectiveness of a novel virtual reality (VR) based intervention; 3D Therapy Thrive (3DTT). Inpatient detoxification can improve outcomes for individuals with opioid use disorder (OUD), however patients often leave treatment early due to mood, tension, and cravings associated with opioid withdrawal. Subjects were recruited from a community inpatient detoxification program and received up to two sessions of 3DTT. The patients completed surveys to assess their mood, distress, cravings, and overall satisfaction with the experience. Retention was measured by protocol completion as reported by clinic staff, independent of the study. A group of patients with OUD consecutively admitted to the program comprised a comparison treatment-as-usual (TAU) group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active VR Group | Active Comparator | Participants received the active virtual therapy intervention. |
|
| Control Group | No Intervention | A group of patients concurrently on the ATS unit, otherwise eligible to participate in the study who did not enroll, and did not receive an intervention. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3D Therapy Thrive | Device | A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Retention in Treatment | Medical record indicating whether patient completed detox protocol (i.e., completed, left against medical advice, administratively discharged, or moved to higher level of care) | At departure from facility, through study completion, an average of 10 days |
| Feasibility and Tolerability of 3DTT | Feasibility and tolerability of 3DTT was measured by the Side Effects Questionnaire. | Immediately after each treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Mood | Depressive symptoms as measured by the AB-POMS depression scale (0-4, not at all to extremely) | Before and after each treatment, approximately every other day for up to 5 days |
| Anxiety | Anxiety symptoms as measured by the AB-POMS scale (0-4, not at all to extremely) |
Not provided
Inclusion Criteria
1.18 years or older
2. Current diagnosis of opioid use disorder
3. Current inpatient in detox ATS unit
4. Fluent in English
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Gavin Foundation | Quincy | Massachusetts | 02170 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Subjects were blinded to study condition.
| Before and after each treatment, approximately every other day for up to 5 days |
| Cravings | Opioid cravings as measured by the Visual Analog Scale (1-10, with higher scores indicating greater cravings.) | Before and after each treatment, approximately every other day for up to 5 days |